Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Doxorubicin
Drug ID BADD_D00723
Description Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius. Doxorubicin binds to nucleic acids, presumably by specific intercalation of the planar anthracycline nucleus with the DNA double helix.
Indications and Usage Doxorubicin is used to produce regression in disseminated neoplastic conditions like acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms’ tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.
Marketing Status approved; investigational
ATC Code L01DB01
DrugBank ID DB00997
KEGG ID D03899
MeSH ID D004317
PubChem ID 31703
TTD Drug ID D07VLY
NDC Product Code 12543-3209; 70121-1218
UNII 80168379AG
Synonyms Doxorubicin | Farmiblastina | Ribodoxo | Rubex | Adriamycin | Adriblastin | Adriblastine | Adriblastina | Adriablastine | Adriablastin | Adrimedac | DOXO-cell | DOXO cell | Urokit Doxo-cell | Urokit Doxo cell | Doxolem | Doxorubicin Hexal | Doxorubicin Hydrochloride | Hydrochloride, Doxorubicin | Doxorubicin NC | Doxorubicina Ferrer Farm | Doxorubicina Funk | Doxorubicina Tedec | Doxorubicine Baxter | Doxotec | Myocet | Onkodox
Chemical Information
Molecular Formula C27H29NO11
CAS Registry Number 23214-92-8
SMILES CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Tumour necrosis24.04.02.013; 16.32.03.0090.000112%Not Available
Skin candida11.03.03.010; 23.11.03.009--Not Available
Affect lability19.04.01.001--Not Available
Transaminases increased13.03.04.036--Not Available
Scrotal erythema23.03.06.013; 21.12.02.008--Not Available
Haemorrhage24.07.01.002--Not Available
Faecaloma07.01.03.004--Not Available
Pulmonary mass22.02.07.0040.000224%Not Available
Chemical cystitis20.03.01.004; 12.03.02.001--Not Available
Faecalith07.01.03.007--Not Available
Pneumatosis intestinalis07.11.01.0430.000112%Not Available
Rectal tenesmus15.05.03.011; 07.03.03.001--Not Available
Paraesthesia oral07.05.05.035; 17.02.06.0080.000302%Not Available
Toxic skin eruption23.03.05.003; 10.01.01.008; 12.03.01.0730.000168%Not Available
Vasodilation procedure25.03.01.001--Not Available
Muscle relaxant therapy25.16.01.001--Not Available
Gastrointestinal toxicity12.03.01.019; 07.08.03.0060.000526%Not Available
Ventricular dysfunction02.04.02.0050.000694%Not Available
Angiopathy24.03.02.007--Not Available
Metastases to central nervous system17.02.10.013; 16.22.02.0040.000504%Not Available
Skin toxicity23.03.03.032; 12.03.01.0200.000616%Not Available
Blood alkaline phosphatase increased13.04.02.004--
Urine output13.13.03.003--Not Available
Hot flush24.03.01.005; 21.02.02.001; 08.01.03.027--
Recall phenomenon23.03.07.005; 12.02.06.001--
Adverse event08.06.01.0100.002115%Not Available
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.11.01.0030.001735%Not Available
Connective tissue disorder15.06.01.006; 10.04.04.026--Not Available
Ocular toxicity12.03.01.031; 06.11.01.006--Not Available
The 20th Page    First    Pre   20 21 22 23 24    Next   Last    Total 25 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene